The original evaluation of rates of hypoglycemia with IDeg (22) reported in a preplanned meta-analysis of pooled patient-level data included the 7 trials in the IDeg phase 3 clinical development program (BEGINTM) (23-29); these were randomized, open-label, treat-to-target trials of 26- or 52-weeks duration comparing once-daily IDeg with once-daily IGlar. IDeg was administered once daily with the main evening meal (or between the start of the main evening meal and bedtime in trial 3586), whereas IGlar was administered once daily, at the same time every day, according to approved labeling.